Phase 2 Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
Phase 2
90
about 4.4 years
18+
Male only
1 site in CA
What this study is about
This trial is testing a flexible dosing schedule of the drug 177Lu-PSMA-617 for men with advanced prostate cancer that has not responded to other treatments. It compares this flexible approach to a standard, fixed dosing schedule. The goal is to see if patients can benefit from more treatment cycles than originally planned.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Gallium Ga 68 Gozetotide
- 2.Questionnaire Administration
- 3.Take Lutetium Lu 177 Vipivotide Tetraxetan
- +3 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You are randomly assigned, but you will know your treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
gallium (68Ga) gozetotide, lutetium (177Lu) vipivotide tetraxetan
Secondary: Bone pain level, DCR by combined radiographic + PSA response, Disease control rate (DCR), Health related quality of life (major symptoms/toxicities), Health related quality of life (pain), Incidence of adverse events, Overall survival, Performance status
imaging